Organon & Co. (NYSE:OGN) Sees Significant Decrease in Short Interest

Organon & Co. (NYSE:OGN) was the recipient of a large decline in short interest in the month of April. As of April 15th, there was short interest totaling 18,609,663 shares, a decline of 15.9% from the March 31st total of 22,133,518 shares. Approximately 7.3% of the company’s shares are short sold. Based on an average trading volume of 9,901,209 shares, the short-interest ratio is currently 1.9 days.

Key Stories Impacting Organon & Co.

Here are the key news stories impacting Organon & Co. this week:

• Positive Sentiment: Board declared a quarterly cash dividend of $0.02 per share (record May 11, payable June 11), implying an annualized yield of ~0.6% — a modest shareholder return that supports income-focused holders.
• Neutral Sentiment: Company press release provides the quarter’s segment detail: total revenue $1.46B (down ~4% vs. Q1 2025). Women’s Health revenue fell ~16% (≈19% ex-FX), Biosimilars grew ~23% (≈21% ex-FX), Established Brands declined ~1% (≈7% ex-FX). Useful for modeling near-term product-level trends. Organon Reports Results for the First Quarter Ended March 31, 2026
• Neutral Sentiment: Analyst write-ups (Zacks and snapshot pieces) dig into how headline numbers compare with estimates and prior year metrics — helpful for gauging margin drivers and consensus revisions. Organon (OGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
• Negative Sentiment: Reported Q1 EPS of $0.71 missed consensus ~$0.83 and declined from $1.02 a year ago; revenue $1.46B missed ~$1.49B. Net margin compressed (~3.0%) though ROE is elevated (122%) — the miss and weakening Women’s Health sales are the main near-term headwinds for forecasts and valuation. Organon (OGN) Q1 Earnings and Revenues Miss Estimates
• Negative Sentiment: High-profile negative commentary (e.g., Jim Cramer quoted as saying “Organon’s done” in a caller exchange) may amplify retail selling or sentiment volatility short-term. Jim Cramer Says “Organon’s Done” Upon a Caller’s Inquiry

Organon & Co. Stock Up 0.3%

Shares of NYSE OGN opened at $13.29 on Friday. Organon & Co. has a 52-week low of $5.69 and a 52-week high of $13.39. The firm has a fifty day moving average of $7.68 and a 200-day moving average of $7.75. The stock has a market capitalization of $3.49 billion, a PE ratio of 14.29, a P/E/G ratio of 1.23 and a beta of 1.57. The company has a quick ratio of 1.23, a current ratio of 1.82 and a debt-to-equity ratio of 11.47.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Thursday, April 30th. The company reported $0.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.83 by ($0.12). Organon & Co. had a net margin of 3.99% and a return on equity of 103.27%. The company had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same period in the prior year, the firm earned $1.02 earnings per share. The firm’s quarterly revenue was down 3.5% on a year-over-year basis. On average, analysts anticipate that Organon & Co. will post 3.23 EPS for the current year.

Organon & Co. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Stockholders of record on Monday, May 11th will be paid a dividend of $0.02 per share. The ex-dividend date of this dividend is Monday, May 11th. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. Organon & Co.’s payout ratio is currently 8.60%.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Barclays boosted their target price on shares of Organon & Co. from $7.50 to $8.00 and gave the company an “underweight” rating in a report on Tuesday, February 24th. Wall Street Zen downgraded shares of Organon & Co. from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. BNP Paribas Exane reissued a “neutral” rating and set a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a research note on Wednesday. Piper Sandler raised shares of Organon & Co. from an “underweight” rating to a “neutral” rating and boosted their price objective for the company from $5.00 to $14.00 in a research note on Tuesday, April 28th. Finally, Zacks Research raised shares of Organon & Co. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 14th. Four research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce” and an average target price of $11.40.

Hedge Funds Weigh In On Organon & Co.

Several hedge funds and other institutional investors have recently made changes to their positions in OGN. Rexford Capital Inc. raised its position in Organon & Co. by 14.9% in the third quarter. Rexford Capital Inc. now owns 11,380 shares of the company’s stock valued at $122,000 after purchasing an additional 1,480 shares during the period. Amalgamated Bank raised its position in Organon & Co. by 1.9% in the third quarter. Amalgamated Bank now owns 79,805 shares of the company’s stock valued at $852,000 after purchasing an additional 1,514 shares during the period. State of Alaska Department of Revenue raised its position in Organon & Co. by 0.6% in the fourth quarter. State of Alaska Department of Revenue now owns 278,379 shares of the company’s stock valued at $1,995,000 after purchasing an additional 1,570 shares during the period. Integrated Wealth Concepts LLC raised its position in Organon & Co. by 2.8% in the third quarter. Integrated Wealth Concepts LLC now owns 58,648 shares of the company’s stock valued at $626,000 after purchasing an additional 1,594 shares during the period. Finally, Arizona State Retirement System raised its position in Organon & Co. by 2.2% in the third quarter. Arizona State Retirement System now owns 76,924 shares of the company’s stock valued at $822,000 after purchasing an additional 1,644 shares during the period. Institutional investors and hedge funds own 77.43% of the company’s stock.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.